Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company...
-
BOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...
-
Reported Third Quarter 2019 Global Net Product Revenues of $12 Million WAYLIVRA® (volanesorsen) launched in the E.U. Entered into a worldwide licensing agreement with Pfizer, Inc. for...
-
BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today recognizes Familial Chylomicronemia...
-
BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that the company has promoted Kyle Jenne...
-
BOSTON, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, November...
-
BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE:PFE),...
-
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has...